Profund Advisors LLC Has $818,000 Stock Holdings in Novavax, Inc. $NVAX

Profund Advisors LLC grew its position in Novavax, Inc. (NASDAQ:NVAX) by 117.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 121,693 shares of the biopharmaceutical company’s stock after purchasing an additional 65,631 shares during the period. Profund Advisors LLC owned about 0.07% of Novavax worth $818,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC lifted its position in Novavax by 7.3% during the 4th quarter. ProShare Advisors LLC now owns 51,710 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 3,532 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Novavax by 6.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,663 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 2,100 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Novavax by 18.9% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,620 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 5,820 shares in the last quarter. Strs Ohio lifted its position in Novavax by 22.4% during the 4th quarter. Strs Ohio now owns 106,000 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 19,400 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its position in Novavax by 161.7% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 89,182 shares of the biopharmaceutical company’s stock worth $599,000 after buying an additional 55,110 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVAX. Weiss Ratings downgraded shares of Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. HC Wainwright upped their price target on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. TD Cowen upped their price target on shares of Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.13.

Novavax Trading Down 3.1%

Shares of NASDAQ NVAX opened at $8.98 on Friday. The firm has a market capitalization of $1.48 billion, a PE ratio of -15.48 and a beta of 2.37. Novavax, Inc. has a 1 year low of $6.13 and a 1 year high of $11.97. The firm’s 50-day moving average is $8.88 and its 200-day moving average is $8.26.

Novavax (NASDAQ:NVAX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.19. The company had revenue of $118.90 million for the quarter, compared to analyst estimates of $79.81 million. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The company’s revenue for the quarter was down 79.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.93 EPS. As a group, equities research analysts anticipate that Novavax, Inc. will post -0.2 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.